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Abstract
Background: Multiple iterations of chimeric antigen receptors (CARs) have been developed, mainly focusing on
intracellular signaling modules. However, the effect of non-signaling extracellular modules on the expansion and
therapeutic efficacy of CARs remains largely undefined.
Methods: We generated two versions of CAR vectors, with or without a hinge domain, targeting CD19, mesothelin,
PSCA, MUC1, and HER2, respectively. Then, we systematically compared the effect of the hinge domains on the
growth kinetics, cytokine production, and cytotoxicity of CAR T cells in vitro and in vivo.
Results: During in vitro culture period, the percentages and absolute numbers of T cells expressing the CARs
containing a hinge domain continuously increased, mainly through the promotion of CD4+ CAR T cell expansion,
regardless of the single-chain variable fragment (scFv). In vitro migration assay showed that the hinges enhanced
CAR T cells migratory capacity. The T cells expressing anti-CD19 CARs with or without a hinge had similar antitumor
capacities in vivo, whereas the T cells expressing anti-mesothelin CARs containing a hinge domain showed
enhanced antitumor activities.
Conclusions: Hence, our results demonstrate that a hinge contributes to CAR T cell expansion and is capable of
increasing the antitumor efficacy of some specific CAR T cells. Our results suggest potential novel strategies in CAR
vector design.
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Background
In the last 5 years, chimeric antigen receptor (CAR) T cells
have emerged from bench to bedside and made headlines
in clinical trials at a number of academic institutions [1–4].
CARs are recombinant receptors that specifically target
tumor-surface antigens. Once the CARs are transfected
into T cells, the cells acquire supraphysiologic properties
and act as “living drugs” [5, 6]. Multiple iterations of CARs
have been developed, mainly focusing on intracellular sig-
naling modules, which are deemed crucial for CAR design
[7, 8]. To achieve appropriate costimulatory signals so as to
activate effector T cells, improve response, and prolong per-
sistence, many different kinds of costimulatory receptors
can be incorporated (e.g., CD28 [9, 10], 4-1BB [11, 12],
OX40 [13], ICOS [14], and CD27 [15]), alone or in tandem
[16]. However, the effect of non-signaling extracellular
modules, such as hinge and TM domains, on the prolifera-
tion of the transduced T cells and therapeutic efficacy of
CARs remains largely unclear [17].
A hinge domain is a structure between the targeting
moiety and the T cell plasma membrane [18]; these
sequences are generally derived from IgG subclasses
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(such as IgG1 and IgG4), IgD and CD8 domains, of which
IgG1 has been most extensively used [19–21]. Currently,
studies of the hinge domain mainly focus on the following
four aspects: (1) reducing binding affinity to the Fcγ re-
ceptor, thereby eliminating off-target activation [19, 21];
(2) enhancing the single-chain variable fragment (scFv)
flexibility, thereby relieving the spatial constraints between
tumor antigens and CARs, in turn promoting synapse
formation between the CAR T cells and target cells; for
example, to overcome steric hindrance in MUC1-specific
CAR, a flexible and elongated hinge of the IgD isotype
can be inserted [20]; (3) reducing the distance between an
scFv and the target epitope, for example, anti-CD22 CAR
needs a hinge domain to exert optimal cytotoxicity [22];
and (4) facilitating the detection of CAR expression using
anti-Fc reagents. Nevertheless, the influences of the hinge
domain on CAR T cell physiology are not well
understood.
To better understand the effect of the hinge domain
on CAR T cells, we generated two versions of CARs,
with or without a hinge domain, targeting CD19,
mesothelin, PSCA (prostate stem cell antigen), MUC1,
and HER2 (human epidermal growth factor receptor 2),
respectively [23–31]. We systematically compared the
effect of the hinge domains on the growth kinetics, cyto-
kine production, and cytotoxicity of CAR T cells in vitro
and in vivo. We revealed that the incorporation of a
hinge into CAR constructs can substantially increase the
CAR T cell percentage during the in vitro culture period,
enhance the invasiveness of CAR T cells. In addition, we
found that anti-CD19 CAR T cells with or without a
hinge domain have similar abilities to eliminate leukemia
cells, whereas a hinge domain can enhance the in vivo
antitumor activity of anti-mesothelin CAR T cells.
Methods
Cells and culture conditions
NALM6-GL (acute lymphoblastic leukemia line, stably
transfected with GFP and luciferase) and A549-GL (human
lung cancer cell line, stably transfected with GFP and lucif-
erase) cell lines were cultured in RPMI-1640 (Gibco, Life
Technologies). HEK293T cells used for lentivirus produc-
tion were cultured with DMEM (Gibco, Life Technologies).
DMEM and RPMI-1640 media were supplemented with
10% heat-inactivated FBS (Gibco, Life Technologies),
10 mM of HEPES, 100 U/ml of penicillin, 100 μg/ml of
streptomycin, and 2 mM of L-glutamine (Gibco, Life
Technologies).
Human peripheral blood mononuclear cells (PBMCs)
from healthy donors were obtained from Guangdong
General Hospital, after obtaining informed consent and
for research use only. Pan T cells were enriched from
the PBMCs using a “Pan T cell isolation kit” (Miltenyi
Biotec, Germany). CD8+ T cells were positively isolated
from the Pan T cells using “CD8 microbeads” (Miltenyi
Biotec, Germany); the unlabeled cells that passed
through the column were collected, representing the
CD4+ T cells.
Construction of chimeric antigen receptors (CARs)
CD19.28z, Meso.28z, HER2.28z, and PSCA.28z CARs
were constructed by linking sequences from a signal
peptide derived from GM-CSF (GenBank; AAA58735.1,
aa 1–19) to the corresponding antigen-specific single-
chain variable fragment (scFv); these CARs do not have
a spacer domain. Anti-CD19 scFv derived from FMC63
monoclonal antibody, anti-Mesothelin scFv derived from
SS1 monoclonal antibody, anti-HER2 scFv derived from
FRP5 monoclonal antibody, and PSCA scFv derived
from humanized 1G8 monoclonal antibody. The CARs
were codon-optimized and chemically synthesized using
Genscript. A spacer containing a hinge domain and a
CH3 domain derived from human IgG4 (GenBank;
AAC82527.1, aa 98–329) was included in PSCA-H.28z
CAR; an additional IgD hinge spacer was included in
MUC1-H.28z CAR. The scFv of anti-MUC1 CAR de-
rived from HMFG2 monoclonal antibody. The resulting
products were sub-cloned into a Pwpxld-based lentiviral
backbone plasmid encoding the transmembrane and
intracellular domains of CD28 (aa 153–220) and the
intracellular domain of CD3-ζ (aa 52–163). CD19-H.28z
CAR and Meso-H.28z CAR were constructed by over-
lapping PCR, adding the hinge domain and the CH3 of
IgG4 to the 3′ end of the scFv.
Lentiviral production and transduction
Pwpxld (encoding the CARs or GFP), Pspax2 (expressing
the three required lentiviral proteins), and PMD.2G (en-
coding the lentiviral envelope protein) were transfected
into HEK293T cells with PEI reagent (Life Technologies).
The lentiviral supernatants were collected 48 and 72 h
after transfection and were passed through a 0.4 μm filter.
Human Pan T cells, CD8+ T cells, or CD4 T cells
were stimulated with microbeads loaded with anti-
human CD3, anti-human CD2, and anti-human CD28
antibodies (Miltenyi Biotec, Germany) in a 3:1 bead:-
cell ratio for 72 h and cultured in RPMI 1640,
supplemented with 10% FBS, 10 mM of HEPES,
100 U/ml of penicillin, 100 μg/ml of streptomycin,
2 mM of L-glutamine, r-human IL-2 (300 IU/ml,
PeproTech, CT, USA), and r-human IL-15 (5 ng/ml,
PeproTech, CT, USA). On day 3 after cell activation,
the activated T cells were transduced with lentiviral
supernatants and Polybrene 8 μg/ml (Takara) once;
then, the cells were washed with PBS 3 times to com-
pletely remove any residual lentiviral supernatants.
The cells were then resuspended in complete medium
to achieve the expansion. The microbeads were
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removed on day 5. Fresh medium was added every
2 days to maintain an appropriate cell density ranging
from 5 × 105 to 1 × 106 cells/ml.
Flow cytometry
All of the samples were analyzed with an LSR Fortessa
or C6 (BD Bioscience), and the data were analyzed using
FlowJo software. CAR T cells were detected by GFP, and
T cell phenotypes were evaluated via CD3 PE-cy7 (clone
OKT3, eBioscience), CD3 BV421 (clone UCHT1, BD),
CD8a PE (clone HT8a, eBioscience), CD8a PE-cf594
(clone RPA-T8, BD), and CD4 APC (clone OKT4,
eBioscience). All FACS plots representing the CAR T cell
phenotypes were gated on CD3 and GFP double positive
cells.
In vitro tumor-killing assays and cytokine-release assays
The target leukemia cells, NALM6-GL, were co-cultured
with GFP T, 19.28z, or 19-H.28z T cells at the indicated
E:T ratios in triplicate in U-bottomed 96-well plates for
18 h; A549-GL cells were co-cultured with GFP T,
Meso.28z T, or Meso-H.28z T cells, each well of 96-well
plates contained 200 μl supernatants. One hundred
microliter supernatants from the wells with E:T ratios of
1:1 were collected and used for detecting the concentra-
tions of IL-2 and IFN-γ using an ELISA kit
(eBioscience). The luciferase substrate D-luciferin (potas-
sium salt, 150 μg/ml, Cayman Chemical, USA) was
added to a 100 μl/well, and the viability of the target
cells was monitored by a microplate reader at a 450-nm
excitation wavelength. The background luminescence
was negligible (<1% of the signal from the wells with
only target cells); therefore, the target cell viability (%)
was calculated as (experimental signal/maximal signal) ×
100%, and the killing percentage was calculated as 100%
− viability percentage.
Transwell cell migration assay
For the 19.28z T and 19-H.28z T cells, Nalm6 cell lysates
were used as a chemoattractant in the lower chamber,
while for the Meso.28z T and Meso-H.28z T cells, A549
cell lysates were used as a chemoattractant in the lower
chamber. The T cells were cultured in an insert coated
with Matrigel for 24 h, and the cells that transmigrated
to the lower chamber were counted by flow cytometry.
The percentage of migration was calculated as follows:
(CAR T cells migrating through the Matrigel chamber
membrane/total CAR T cells in insert membrane before
assay begin) × 100.
In vivo studies
NSI mice (NOD-scid-IL2Rg−/−mice, Guangzhou Institutes
of Biomedicine and Health (GIBH)), aged 6–12 weeks
were used to construct the xenograft tumor mouse
models. All of the animal studies were carried out in ac-
cordance with instructional guidelines from the China
Council on Animal Care and under protocols approved by
the guidelines of the Ethics Committee of Animal Ex-
periments at GIBH. Equivalent numbers of male and
female mice were used. The NALM6-GL leukemia
lines were intravenously inoculated into 2 × 105 cells,
and the A549-GL carcinoma lines were inoculated
into 5 × 105 cells subcutaneously (flank). The mice
then received an adoptive transfer of CAR T cells
intravenously 3–14 days later, as indicated in the indi-
vidual experiments. To control the differences in
transduction efficiency, non-transduced T cells were
supplemented to ensure that both the number of
CAR+ T cells, and the total number of T cells
remained constant across all CAR T cell groups. The
leukemia burden was evaluated using a cooled CCD
camera system (IVIS 100 Series Imaging System,
Xenogen, Alameda, CA, USA). The mice were
injected intraperitoneally with D-luciferin firefly potas-
sium salt at 75 mg/kg and then imaged 5 min later
with an exposure time of 30 s. Quantification of the
total and average emissions was performed using
Living Image software (Xenogen).
Statistics
All graphs report the mean ± SEM. All statistical ana-
lyses were performed with Prism software version 6.0
(GraphPad). The statistical significance of all data was
calculated using an unpaired Student’s t test with the
Bonferroni correction for multiple comparisons, where
applicable. P < 0.05 was considered significant and is
designated with an asterisk in all figures.
Results
Hinge incorporation can promote the growth of CAR T cells
To characterize the functionality of hinges in CAR
vectors, we constructed a series of lentiviral vectors
for CAR production that contained the same trans-
membrane and intracellular domains (CD28 costimu-
latory receptor in tandem with CD3ζ) but different
scFv-binding and hinge domains, tagged with GFP
(Fig. 1a). We then transduced these CAR vectors into
human primary T cells and monitored the growth of
the CAR T cells from day 6 post-transfection. Inter-
estingly, we found that the percentages of CAR T cells
were greater when the CAR vectors contained a hinge do-
main, regardless of the scFv. For example, the percentages
of 19-H.28z and Meso-H.28z T cells increased from 3.0 to
40.7% (Fig. 1b; Additional file 1: Figure S1) and from 34 to
74.3% (Fig. 1c; Additional file 1: Figure S1), respectively. In
addition, the percentages of PSCA-H.28z T cells increased
from 4.7 to 31.1% (Fig. 1d; Additional file 1: Figure S1) and
from 1.6 to 58.2% (Fig. 1i). Similarly, the percentages of
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MUC1-H.28z T cells also increased from 6.9 to 17.3%, al-
though the MUC1-H.28z CAR was designed with an IgD
hinge, which indicates that the ability to increase the CAR
T cell percentage is not restricted to IgG4-CH3 hinges
(Fig. 1i). The absolute number of CAR T cells also signifi-
cantly increased (Fig. 1e–g). In contrast, the percentages of
CAR T cells without a hinge domain tended to be stable
throughout the in vitro expansion process (Fig. 1b–d;
Additional file 1: Figure S1), and their total cell numbers
were less than those of CAR T cells containing a hinge
domain (Fig. 1e–g). Taken together, these results demon-
strate that the incorporation of a hinge domain can
promote the growth of CAR Tcells in vitro.
Hinge incorporation mainly promotes CD4+ CAR T cell
expansion
To identify which T cell subsets were most responsive to
the incorporation of a hinge domain, we monitored the
ratios of CD4+ and CD8+ CAR T cells in culture and
found that the percentages of CD4+ 19-H.28z T and
Fig. 1 Hinge incorporation can promote the expansion of CAR T cells. a Schematic representation of CAR constructs specific for different
antigens, and with or without a hinge domain. Flow cytometric analysis of the percentage of (b) 19.28z, 19-H.28z T cells, (c) Meso.28z, Meso-H.28z
T cells, (d) PSCA.28z, PSCA-H.28z T cells, and GFP control T cells from day 6 to 15 during the in vitro culture period. The data are representative of
independent experiments verified with cells from over three individual healthy human donors. Total cell number of (e) 19.28z T and 19-H.28z T
cells, (f) Meso.28z T and Meso-H.28z T cells, (g) PSCA.28z T, and PSCA-H.28z T cells from day 4 to day 16 during the in vitro culture period. Error
bars denote the SEM, and the results were compared through an unpaired t test. *P < 0.05, **P < 0.01, and ***P < 0.001. Flow cytometric analysis
of the percentage of (h) 19.28z T, Meso.28z T, HER2.28z T cells, (i) PSCA-H.28z T, MUC1-H.28z T, and GFP control T cells from day 6 to 21 during
the in vitro culture period. The data are representative of independent experiments verified with cells from over three individual healthy
human donors
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CD4+ Meso-H.28z T cells increased from 3.13 to 29.6%
(Fig. 2a, left; Additional file 2: Figure S2) and from 19.9
to 46.5% (Fig. 2a, middle), respectively. In addition, the
percentages of CD4+ PSCA-H.28z T cells increased
from 3.06 to 34.3% (Fig. 2a, right) and from 0.92 to
46% (Fig. 2b, left). The CD4+ MUC1-H.28z T cells
also increased from 4.14 to 14.9% (Fig. 2b, right).
However, the influence of the hinge domain on the
percentages of CD8+ CAR T cells was less pro-
nounced, as the percentages of CD8+ 19-H.28z T and
CD8+ Meso-H.28z T cells increased from 0.4 to
10.5% (Fig. 2a, left; Additional file 2: Figure S2) and
from 14.1 to 23.8% (Fig. 2a, middle), respectively. In
addition, the CD8+ PSCA-H.28z T cells increased
from 0.92 to 6.34% (Fig. 2a, right) and from 0.67 to
12.6% (Fig. 2b, left). The CD8+ MUC1-H.28z T cells
also increased from 2.85 to 4.61% (Fig. 2b, right). The
percentage of CAR T cells without a hinge domain
tended to be stable throughout the in vitro culture
period (Additional file 3: Figure S3). Interestingly,
when we isolated CD4+ T and CD8+ T cells and
cultured them separately in vitro, the percentages of
CAR T cells with or without a hinge domain all
tended to be stable in both CD4+ T and CD8+ T
cells, consistent with the GFP control T cells (Fig. 2c).
This suggests that the use of a hinge to enhance CD4
+ CAR T cell expansion requires the co-participation
of CD8+ CAR T cells. In summary, hinge incorpo-
ration mainly promotes CD4+ CAR T cell expansion
during the in vitro culture period.
Hinge incorporation can enhances migratory capacity of
CAR T cells
To study whether the incorporation of a hinge domain af-
fects the cytotoxicity of CAR T cells, we compared the
killing capacities of anti-CD19 and anti-mesothelin CARs
with and without a hinge. Both 19.28z T and 19-H.28z T
cells efficiently lysed the NALM6-GL (Fig. 3a), indicating
that the killing capacities of these two CARs were similar.
Similarly, there were no significant differences between
the lysis capacities of Meso.28z T and Meso-H.28z CAR T
cells (Fig. 3b). For cytokine production, both 19-H.28z T
and Meso-H.28z T cells produced similar levels of IL2 and
IFN-γ compared with their hinge-free counterparts
Fig. 2 Hinge incorporation mainly promotes CD4+ CAR T cell expansion. a Flow cytometric analysis of the percentage of CD4+ and CD8+ 19-H.28z T
(left), Meso-H.28z T (middle), and PSCA-H.28z T (right) during the in vitro culture period. Black box represents CD4+ T cell and gray box represents CD8+
T cells. The data are representative of independent experiments verified with cells from over three individual healthy human donors. b Flow cytometric
analysis of the percentage of CD4+ and CD8+ PSCA-H.28z T (left) and MUC1-H.28z T cells (right) during the in vitro culture period. Black box represents
CD4+ T cell and gray box represents CD8+ T cells. The data are representative of independent experiments verified with cells from over three individual
healthy human donors. c Flow cytometric analysis of the percentage of CD4+ and CD8+ GFP T, 19.28z T, 19-H.28z T, PSCA.28z T, and PSCA-H.28z T cells
when CD4+ T and CD8+ T cells were isolated and cultured them separately in vitro. The data are representative of independent experiments verified
with cells from over three individual healthy human donors
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Fig. 3 A hinge enhances the migratory capacity of CAR T cells. Cytotoxicity of (a) 19.28z T, 19-H.28z T, and control GFP T cells after co-culture with
CD19+ cell line (NALM6-GL) for 24 h, (b) Meso.28z T, Meso-H.28z T, and control GFP T cells after co-culture with mesothelin + cell line (A549-GL)
for 24 h. E:T ratios are the ratios of the absolute number of CAR T cells to the target cells. The GFP percentages of the CAR T cells were equalized
using non-transduced T cells from the same donor. n = 3 replicates per point; the data are representative of independent experiments verified
with cells from over three individual healthy human donors. IL2 production of (c) 19.28z T, 19-H.28z T, and control GFP T cells after co-culture with
CD19+ cell line (NALM6-GL) for 24 h, (d) Meso.28z T, Meso-H.28z T, and control GFP T cells after co-culture with mesothelin + cell line (A549-GL)
for 24 h. IFN-γproduction of (e) 19.28z T, 19-H.28z T, and control GFP T cells after co-culture with CD19+ cell line (NALM6-GL) for 24 h, (f) Meso.28z
T, Meso-H.28z T, and control GFP T cells after co-culture with mesothelin + cell line (A549-GL) for 24 h. CAR T cells were co-cultured with the
targeted tumor cells at a 1:1 E: T ratio. n = 3 replicates per point; the data are representative of independent experiments verified with cells from
over three individual healthy human donors. Error bars denote the SEM, and the results were compared through an unpaired t test. *P <
0.05, **P < 0.01, and ***P < 0.001. Transwell cell migration assay indicated an improved capacity of (g) 19-H.28z T cells, (h) Meso-H.28z T
cells to transmigrate Matrigel. For the 19.28z T and 19-H.28z T cells, Nalm6 cell lysates were used as a chemoattractant in the lower
chamber, while for the Meso.28z T and Meso-H.28z T cells, A549 cell lysates were used as a chemoattractant in the lower chamber. The T
cells were cultured in an insert coated with Matrigel for 24 h, and the cells that transmigrated to the lower chamber were counted by
flow cytometry. The percentage of migration was calculated as follows: (CAR T cells migrating through the Matrigel chamber membrane/
total CAR T cells in insert membrane before assay begin) × 100. n = 3 replicates per point; the data are representative of independent
experiments verified with cells from over three individual healthy human donors. Error bars denote the SEM, and the results were
compared through an unpaired t test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001
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(Fig. 3c–f ). Next, we compared the migratory capacity of
GFP T, 19.28z T, and 19-H.28z T cells, using NALM6 cell
lysate as a chemoattractant in the lower chamber of the
transwell plate. Interestingly, we found that the 19-H.28z
T cells transmigrated the Matrigel more efficiently than
the 19.28z T cells (Fig. 3g). Similar results were also ob-
tained in the Meso-H.28z T cells (Fig. 3h), suggesting that
hinge incorporation enhanced the migratory and invasion
capabilities of CAR T cells.
19-H.28z T and 19.28z T cells have comparable anti-tumor
efficacy in vivo
Subsequently, we evaluated the in vivo antitumor capaci-
ties of CAR T cells with or without the hinge domain in
cell-line-derived xenograft-bearing mice. Immune defi-
cient NSI mice were intravenously injected with 2 × 105
NALM6-GL cells, followed by the infusion of a single
dose of 2 × 106 GFP, 19.28z, or 19-H.28z T cells on day 7
(Fig. 4a) [32–36]. Bioluminescence imaging (BLI)
showed a reduced tumor burden in the mice infused
with 19.28z T and 19-H.28z T cells compared with those
infused with GFP T cells on day 14. However, both the
19.28z T and 19-H.28z T-cell-infused mice relapsed on
day 22 (Fig. 4c). The survival times of the 19.28z T and
19-H.28z T cell groups also showed no significant differ-
ence (Fig. 4b). In summary, the introduction of a hinge
into anti-CD19 specific CARs did not enhance their in
vivo antitumor capacities.
Meso-H.28z T cells exhibit enhanced antitumor capacities
in vivo
To study whether a hinge can affect the antitumor
capacities of CARs that are specific for solid tumors, a
solid-tumor mouse model was established, in which
A549-GL cells were subcutaneously injected into NSI
mice. Mice bearing an established tumor were treated
I.V. with two doses of Meso.28z, Meso-H.28z, or GFP T
cells, with the first dose on day 7 and the second on day
10. The tumor diameters were measured every 6 days.
On day 49, the mice were sacrificed (Fig. 5a). Interest-
ingly, tumor growth in both the Meso.28z T and Meso-
H.28z T cell groups was delayed compared with the
blank and GFP T cell group, but the delay was greater in
the Meso-H.28z T group (Fig. 5b). Results consistent
with these were also obtained from weight measurement
and photographic inspection of the tumors (Fig. 5c–d).
Fig. 4 19-H.28z T and 19.28z T cells have comparable antitumor efficacy in vivo. a Timeline and events of the experiment with intravenous
NALM6-GL xenograft models. On day 0, 2 × 105 NALM6-GL cells were injected through the tail vein into the NSI mice, and on day 7, 2 × 106 GFP
T, 19.28z T or 19-H.28z T cells were injected through the tail vein into each NALM6-GL-NSI mouse. The cell numbers refer to transduced CAR T
cells. n = 3 for the GFP T cell group, and n = 4 for the 19.28z T and 19-H.28z T cell group. On day 7, 14, 22, and 33, bioluminescence imaging was
conducted. b Survival analysis of mice treated with GFP T, 19.28z T, or 19-H.28z T cells. c Bioluminescence images of mice treated with GFP T,
19.28z T, or 19-H.28z T cells on day 7, 14, 22, and 33 post-infusion of 2 × 105 NALM6-GL cells
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These results demonstrated that the incorporation of a
hinge domain enhanced the antitumor capacities of anti-
mesothelin CARs.
Discussion
Despite the remarkable progress in CAR T cell-based
immune therapy, several obstacles remain [37, 38]. For
example, the efficiency of CAR T cell expansion requires
improvement. Recently, some groups have reported that
an optimal CD4/CD8 ratio is important for the in vivo
antitumor activity of CAR T cells, and the percentage of
CD4+ CAR T cells is positively correlated with patient
recovery rates [39–42]. Because CD8+ T cells tend to be
preferentially expanded in current T cell in vitro culture
systems [43], a method to promote the expansion of
CD4+ T cells is urgently needed. Herein, we found that
both IgG4-CH3 and IgD hinges were able to continu-
ously increase the CAR T cell percentages and absolute
cell numbers during the in vitro culture period [20, 44],
and even more importantly, the additional CAR T cells
were mainly CD4+. However, when we isolated the CD4
+ T and CD8+ T cells and cultured them separately in
vitro, the increased-growth effect disappeared. The
mechanism of the increased growth will be studied by us
in the future.
To date, many different versions of anti-CD19 CARs
have been used in clinical trials [38]. The scFvs of these
CARs are almost all derived from FMC63 mAb [45],
while various different hinge domains and costimulatory
molecules have been used. For example, CTL019, which
is the most widely used CAR in CD19+ leukemia and
lymphoma treatment, has a CD8α hinge [46, 47], while
CD19RCD28 CAR uses a modified IgG4 hinge and Fc
region [48], and also has a hinge-deleted version [19].
The functional differences between CD28 and 41-BB
costimulatory molecules have already been well charac-
terized [49]; however, the influence of the hinge domain
on anti-CD19 CARs has not been studied. Our results
showed that the killing activities of 19.28z T and 19-H.28z
T cells were similar whether in vitro or in vivo. There are
several possible explanations of this result: the location of
the CD19 epitope recognized by the FMC63 mAb is not
membrane-proximal, there are no steric inhibitory effects
between FMC63 mAb and its epitope, or the density of
the CD19 molecule on tumor cells is high [50]. These
factors may also partially explain the greater popularity of
CD19 in clinical trials compared with CD20 and CD22.
Mesothelin is a glycosyl–phosphatidyl inositol-linked
cell surface glycoprotein, which is highly expressed in
mesothelioma, and lung, pancreas, breast, ovarian, and
other cancers, and has been used as a tumor antigen of
CAR T cells in several trials [51]. We have shown that
Meso-H.28z T cells have a better tumor-eradication
capacity than Meso.28z T cells in tumor-bearing mice,
suggesting that the mesothelin epitope recognized by the
Fig. 5 Meso-H.28z T cells exhibit enhanced antitumor capacities in vivo. a Timeline of events of the xenograft experiment with the subcutaneous
inoculation of A549-GL cells. On day 0, 5 × 105 A549-GL cells were injected subcutaneously into the NSI mice, and on day 7 and day 10, 1 × 106 and
6 × 105 GFP T, Meso.28z T or Meso-H.28z T cells were injected through the tail vein into each mouse (n = 3). The cell numbers refer to transduced CAR
T cells. b Tumor burden of mice treated with GFP T, Meso.28z T, or Meso-H.28z T cells from day 16 to 49 after A549-GL cell inoculation. On day 49, the
mice were sacrificed and the tumors were analyzed. c–d Size and weight of subcutaneous A549-GL tumors from NSI mice treated with GFP T,
Meso.28z T, or Meso-H.28z T cells on day 49 post-inoculation of A549-GL cells. Error bars denote the s.e.m. and the groups were compared through an
unpaired t test. *P < 0.05, **P < 0.01, and ***P < 0.001
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scFv may be membrane-proximal, or that there exist
steric inhibitory effects between scFv and its epitope, like
in SM3 mAb (a MUC1-specific mAb) [20]. Thus, a hinge
is necessary to reduce the distance or ameliorate the
steric inhibitory effects between the scFv and its epitope.
Furthermore, a hinge can also improve the flexibility of
the scFv, which may also be one of the reasons why
Meso-H.28z T cells exhibit better anti-tumor activities
than Meso.28z T cells. The importance of Ab flexibility
has also been demonstrated in naive B cells which co-
express cell surface IgM, which lacks a hinge, and IgD,
whose elongated monomeric hinge is the longest of all
Ab isotypes [52]. As a result, IgD can assume a “T
shape” in which Fab regions can engage Ag in virtually
any orientation, making the scFv omni-directional.
Conclusions
To summarize, our data demonstrate that the incorpo-
ration of a hinge domain can enhance CAR T cell expan-
sion during the in vitro culture period, mainly by
promoting CD4+ CAR T cell proliferation, and a hinge
domain can also enhance the antitumor efficacy of some
specific CARs. Our results suggest potential novel
strategies in CAR vector design.
Additional files
Additional file 1: Figure S1. Hinge incorporation can promote the
expansion of CAR T cells. Flow cytometric analysis of the percentage of
19.28z, 19-H.28z T cells, Meso.28z, Meso-H.28z T cells, PSCA.28z, PSCA-H.28z
T cells, and GFP control T cells from day 6 to 15 during the in vitro culture
period. The data are representative of independent experiments verified
with cells from over three individual healthy human donors. (JPG 2876 kb)
Additional file 2: Figure S2. Hinge incorporation promotes CD4+
anti-CD19 CAR T cell expansion. Flow cytometric analysis of the percentage
of CD4+ and CD8+ GFP T, 19.28z T, and 19-H.28z T during the in vitro
culture period. The data are representative of independent experiments
verified with cells from over three individual healthy human donors.
(JPG 2320 kb)
Additional file 3: Figure S3. Percentages of CD4+ and CD8+ CAR T
cells without a hinge domain both tended to be stable throughout the
in vitro culture period. Flow cytometric analysis of the percentage of CD4
+ and CD8+ (A) 19.28z T, (B) Meso.28z T, (C) PSCA.28z T, (D) HER2.28z T,
and (E) GFP control T cells during the in vitro culture period. The data are
representative of independent experiments verified with cells from over
three individual healthy human donors. (JPG 924 kb)
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